PL360153A1 - Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents - Google Patents
Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agentsInfo
- Publication number
- PL360153A1 PL360153A1 PL36015301A PL36015301A PL360153A1 PL 360153 A1 PL360153 A1 PL 360153A1 PL 36015301 A PL36015301 A PL 36015301A PL 36015301 A PL36015301 A PL 36015301A PL 360153 A1 PL360153 A1 PL 360153A1
- Authority
- PL
- Poland
- Prior art keywords
- antitumors
- agents
- monoclonal anti
- aromatase inhibitors
- her2 antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57135500A | 2000-05-15 | 2000-05-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL360153A1 true PL360153A1 (en) | 2004-09-06 |
Family
ID=24283360
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL36015301A PL360153A1 (en) | 2000-05-15 | 2001-04-19 | Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP1282440A1 (fr) |
JP (1) | JP2003533490A (fr) |
KR (1) | KR20030014223A (fr) |
CN (1) | CN1429118A (fr) |
AU (1) | AU784617B2 (fr) |
BR (1) | BR0110732A (fr) |
CA (1) | CA2409652A1 (fr) |
CZ (1) | CZ20023748A3 (fr) |
EA (1) | EA005931B1 (fr) |
EE (1) | EE200200622A (fr) |
HK (1) | HK1054200A1 (fr) |
HU (1) | HUP0301877A2 (fr) |
IL (1) | IL152389A0 (fr) |
MX (1) | MXPA02011194A (fr) |
NO (1) | NO20025302D0 (fr) |
NZ (1) | NZ523004A (fr) |
PL (1) | PL360153A1 (fr) |
SK (1) | SK16022002A3 (fr) |
WO (1) | WO2001087334A1 (fr) |
ZA (1) | ZA200209815B (fr) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
AUPQ105799A0 (en) | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
CN102698265A (zh) | 2000-05-19 | 2012-10-03 | 杰南技术公司 | 用于提高对ErbB 拮抗剂癌症治疗的有效应答可能性的基因检测试验 |
PT1377298E (pt) * | 2001-01-26 | 2006-12-29 | Pharmacia & Upjohn Co Llc | Exemestano para o tratamento de perturbações hormono-dependentes. |
GB2375958B (en) | 2001-04-09 | 2005-03-02 | George Margetts | The use of steroids to lower the levels of cortisol |
JP4660094B2 (ja) | 2002-03-26 | 2011-03-30 | ゼンサン (シャンハイ) サイ−テク. リミテッド | 新生物を治療するためのErbB3に基づく方法および組成物 |
AU2003279657A1 (en) * | 2002-07-01 | 2004-01-19 | Savient Pharmaceuticals, Inc. | Compositions and methods for therapeutic treatment |
FR2844455B1 (fr) * | 2002-09-13 | 2007-12-14 | Lab Francais Du Fractionnement | Traitement des pathologies echappant a la reponse immune par des anticorps optimises |
EP1802341A1 (fr) * | 2004-07-16 | 2007-07-04 | Pfizer Products Inc. | Traitement combine pour malignites non hematologiques par anticorps anti -ogf-1r |
ES2710439T3 (es) | 2005-01-21 | 2019-04-25 | Genentech Inc | Dosificación fija de anticuerpos HER |
AU2006216732C1 (en) | 2005-02-23 | 2017-07-20 | Genentech, Inc. | Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor |
US20090215731A1 (en) | 2005-10-19 | 2009-08-27 | Chavah Pty Ltd. | Reduction of Side Effects From Aromatase Inhibitors Used for Treating Breast Cancer |
CA2677108A1 (fr) | 2007-03-02 | 2008-09-12 | Genentech, Inc. | Element de prevision de la reponse a un inhibiteur de her |
US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
EP2592156B1 (fr) | 2007-06-08 | 2016-04-20 | Genentech, Inc. | Marqueurs d'expression de gène de résistance tumorale à un traitement par inhibiteur HER2 |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
ES2572728T3 (es) | 2009-03-20 | 2016-06-02 | F. Hoffmann-La Roche Ag | Anticuerpos anti-HER biespecíficos |
SG10201507044PA (en) | 2009-05-29 | 2015-10-29 | Hoffmann La Roche | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
PL2536748T3 (pl) | 2010-02-18 | 2015-01-30 | Genentech Inc | Antagoniści neureguliny i ich zastosowanie w leczeniu nowotworu |
WO2011146568A1 (fr) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Prédiction de réponses à un inhibiteur de her |
WO2012069466A1 (fr) | 2010-11-24 | 2012-05-31 | Novartis Ag | Molécules multi-spécifiques |
JP5766296B2 (ja) | 2010-12-23 | 2015-08-19 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用 |
CN102068429B (zh) * | 2010-12-28 | 2011-12-14 | 西南大学 | 法倔唑在诱导罗非鱼已分化卵巢转变为功能型精巢中的应用及其诱导方法 |
WO2013025853A1 (fr) | 2011-08-17 | 2013-02-21 | Genentech, Inc. | Anticorps anti-neuréguline et utilisations associées |
WO2013063229A1 (fr) | 2011-10-25 | 2013-05-02 | The Regents Of The University Of Michigan | Traitement par un agent de ciblage de her2 dans des cancers non amplifiés par her2 ayant des cellules souches cancéreuses exprimant her2 |
JP2015500638A (ja) | 2011-11-30 | 2015-01-08 | ジェネンテック, インコーポレイテッド | 癌におけるerbb3変異 |
US9376715B2 (en) | 2011-12-09 | 2016-06-28 | Roche Molecular Systems, Inc | Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene |
JP2015514710A (ja) | 2012-03-27 | 2015-05-21 | ジェネンテック, インコーポレイテッド | Her3阻害剤に関する診断及び治療 |
US20160038490A1 (en) * | 2012-07-18 | 2016-02-11 | Angion Biomedica Corp. | Compositions and methods for treating dysproliferative diseases |
CA2889298C (fr) | 2012-11-30 | 2024-01-02 | Anton Belousov | Identification de patients ayant besoin d'une cotherapie par un inhibiteur de pd-l1 |
CN107405353B (zh) | 2014-10-22 | 2021-07-30 | 哈瓦赫治疗有限公司 | 降低乳房摄影乳腺密度和/或乳腺癌风险的方法 |
EP3364978A4 (fr) | 2015-10-22 | 2019-06-05 | Havah Therapeutics Pty Ltd | Procédés de réduction de la densité mammaire à la mammographie et/ou du risque de cancer du sein |
EP3454863A1 (fr) | 2016-05-10 | 2019-03-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Polythérapies pour le traitement du cancer |
CN107417791B (zh) * | 2017-08-17 | 2020-09-22 | 合肥瀚科迈博生物技术有限公司 | 抗人ErbB2双特异性抗体、其制备方法及用途 |
EP3976048A4 (fr) | 2019-06-03 | 2023-07-12 | Havah Therapeutics Pty Ltd | Formulations pharmaceutiques et systèmes pour l'administration d'un agent androgène et d'un inhibiteur de l'aromatase, et procédés d'utilisation |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA9811162B (en) * | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
-
2001
- 2001-04-19 EE EEP200200622A patent/EE200200622A/xx unknown
- 2001-04-19 CZ CZ20023748A patent/CZ20023748A3/cs unknown
- 2001-04-19 PL PL36015301A patent/PL360153A1/xx not_active Application Discontinuation
- 2001-04-19 IL IL15238901A patent/IL152389A0/xx unknown
- 2001-04-19 JP JP2001583801A patent/JP2003533490A/ja not_active Withdrawn
- 2001-04-19 BR BR0110732-1A patent/BR0110732A/pt not_active IP Right Cessation
- 2001-04-19 MX MXPA02011194A patent/MXPA02011194A/es not_active Application Discontinuation
- 2001-04-19 WO PCT/EP2001/004468 patent/WO2001087334A1/fr active IP Right Grant
- 2001-04-19 EA EA200201213A patent/EA005931B1/ru not_active IP Right Cessation
- 2001-04-19 CA CA002409652A patent/CA2409652A1/fr not_active Abandoned
- 2001-04-19 HU HU0301877A patent/HUP0301877A2/hu unknown
- 2001-04-19 SK SK1602-2002A patent/SK16022002A3/sk not_active Application Discontinuation
- 2001-04-19 AU AU56309/01A patent/AU784617B2/en not_active Ceased
- 2001-04-19 KR KR1020027015223A patent/KR20030014223A/ko not_active Application Discontinuation
- 2001-04-19 NZ NZ523004A patent/NZ523004A/en unknown
- 2001-04-19 EP EP01929585A patent/EP1282440A1/fr not_active Withdrawn
- 2001-04-19 CN CN01809581A patent/CN1429118A/zh active Pending
-
2002
- 2002-11-05 NO NO20025302A patent/NO20025302D0/no not_active Application Discontinuation
- 2002-12-03 ZA ZA200209815A patent/ZA200209815B/en unknown
-
2003
- 2003-09-11 HK HK03106504.3A patent/HK1054200A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
SK16022002A3 (sk) | 2003-04-01 |
HK1054200A1 (zh) | 2003-11-21 |
JP2003533490A (ja) | 2003-11-11 |
NO20025302L (no) | 2002-11-05 |
MXPA02011194A (es) | 2003-03-10 |
WO2001087334A1 (fr) | 2001-11-22 |
EE200200622A (et) | 2004-06-15 |
EA005931B1 (ru) | 2005-08-25 |
IL152389A0 (en) | 2003-05-29 |
CA2409652A1 (fr) | 2001-11-22 |
HUP0301877A2 (hu) | 2003-09-29 |
NZ523004A (en) | 2004-09-24 |
CZ20023748A3 (cs) | 2003-04-16 |
NO20025302D0 (no) | 2002-11-05 |
AU5630901A (en) | 2001-11-26 |
AU784617B2 (en) | 2006-05-18 |
KR20030014223A (ko) | 2003-02-15 |
ZA200209815B (en) | 2003-12-03 |
BR0110732A (pt) | 2003-02-04 |
CN1429118A (zh) | 2003-07-09 |
EP1282440A1 (fr) | 2003-02-12 |
EA200201213A1 (ru) | 2003-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1054200A1 (zh) | 芳香酶抑制劑和單克隆抗her2抗體作為抗腫瘤劑 | |
HUP0300841A3 (en) | Agonist anti-trk-c monoclonal antibodies | |
IL158643A (en) | Anti-hmg monoclonal antibodies and compositions containing the same | |
GB0029360D0 (en) | Humanised antibodies and uses thereof | |
IL156030A0 (en) | Humanized antibodies | |
AU1174702A (en) | Humanized anti-lt-beta-r antibodies | |
HK1158219A1 (zh) | 細胞亞群特異單克隆和多克隆抗體的組合物和方法 | |
EP1391464A4 (fr) | Anticorps monoclonal anti-cd40 | |
IL202348A0 (en) | Anti-her2 antibody variants | |
IL149701A0 (en) | Use of anti-ctla-4 antibodies | |
IL166244A0 (en) | Super humanized antibodies | |
EP1448601A4 (fr) | Methodes et compositions d'anticorps monoclonaux specifiques des proteines beta-amyloides | |
EP1572077A4 (fr) | Utilisations d'anticorps 8h9 monoclonaux | |
EP1399187A4 (fr) | Utilisations d'anticorps monoclonal 8h9 | |
AU2002340167A8 (en) | Anti-hla-dr antibodies and the methods of using thereof | |
AU2001277022A1 (en) | Bispecific monoclonal antibodies to il-12 and il-18 receptors | |
AU2001290315A1 (en) | Anti-cd14 monoclonal antibody having effect of inhibiting cd14/tlr binding | |
AU2003220079A8 (en) | Uses of monoclonal antibody 8h9 | |
EP1178829A4 (fr) | Anticorps monoclonal humain | |
FI20011055A0 (fi) | Heveiiniä sitovat monoklonaaliset vasta-aineet | |
EP1393746A4 (fr) | Compositions d'anticorps polyclonaux humains | |
EP1446416A4 (fr) | Anticorps monoclonaux specifiques de tumeur | |
GB0008160D0 (en) | Monoclonal antibodies | |
GB0003359D0 (en) | Monoclonal antibodies | |
GB0030139D0 (en) | Monoclonal antibody |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |